viewSkinBioTherapeutics PLC

Skinbiotherapeutics get set for live data trial to target skin conditions including psoriasis

SkinBioTherapeutics PLC's (LON:SBTX) Stuart Ashman talks to Proactive London about their wholly-owned subsidiary AxisBiotix Limited which is getting ready for their food supplement consumer study.

The study, which will accept around 200 applicants, the participants will be asked to take a powdered food supplement dissolved in a glass of water on a daily basis and the study will run for a total of 56 days (2 x 28-day blocks).

The supplements have been manufactured by Winclove and are currently being packaged ahead of shipment to the company in early February. 

Ashman talks through in detail their drive for commercialisation, with talks already underway.

Quick facts: SkinBioTherapeutics PLC

Price: 29 GBX

Market: AIM
Market Cap: £45.21 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SkinBioTherapeutics PLC named herein, including the promotion by the Company of SkinBioTherapeutics PLC in any Content on the Site, the Company...


SkinBioTherapeutics raise £4m to expand SkinBiotix technology in oral and...

Skinbiotherapeutics Plc's (LON:SBTX) Doug Quinn talks to Proactive's Katie Pilbeam on their plans for the £4m raised from existing and new institutions to fund work on new product applications. Quinn explains how they plan to expand skin biotics technology into oral and healthcare as...

on 14/10/20

2 min read